K L Preston

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi Broad beneficial effects of cocaine abstinence reinforcement among methadone patients
    K Silverman
    Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    J Consult Clin Psychol 66:811-24. 1998
  2. ncbi Opioid discrimination in humans: discriminative and subjective effects of progressively lower training dose
    K L Preston
    Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Behav Pharmacol 9:533-43. 1998
  3. ncbi Shaping cocaine abstinence by successive approximation
    K L Preston
    Intramural Research Program, National Institute on Drug Abuse, Baltimore, Maryland 21224, USA
    J Consult Clin Psychol 69:643-54. 2001
  4. ncbi Cocaine use early in treatment predicts outcome in a behavioral treatment program
    K L Preston
    Intramural Research Program, National Institute on Drug Abuse NIDA, Baltimore, Maryland 21224, USA
    J Consult Clin Psychol 66:691-6. 1998
  5. ncbi Evaluation of the abuse potential of methocarbamol
    K L Preston
    Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland
    J Pharmacol Exp Ther 248:1146-57. 1989
  6. ncbi Monitoring opiate use in substance abuse treatment patients with sweat and urine drug testing
    M A Huestis
    Chemistry and Drug Metabolism Section, National Institute on Drug Abuse Intramural Research Program, Baltimore, Maryland 21224, USA
    J Anal Toxicol 24:509-21. 2000
  7. ncbi Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716
    M A Huestis
    National Institute on Drug Abuse Intramural Research Program, 5500 Nathan Shock Dr, Baltimore, MD 21224, USA
    Arch Gen Psychiatry 58:322-8. 2001
  8. ncbi Family history influence on drug abuse severity and treatment outcome
    R W Pickens
    Clinical Neurogenetics Section and Treatment Research Branch, Intramural Research Program, National Institute on Drug Abuse, Baltimore, MD 21224, USA
    Drug Alcohol Depend 61:261-70. 2001
  9. ncbi Low-dose oral cocaine in humans: acquisition of discrimination and time-course of effects
    D H Epstein
    NIH, NIDA Intramural Research Program, Baltimore, Maryland, USA
    Behav Pharmacol 10:531-42. 1999
  10. ncbi Naltrexone shortened opioid detoxification with buprenorphine
    A Umbricht
    NIDA Intramural Research Program, Addiction Research Center, Baltimore, MD, USA
    Drug Alcohol Depend 56:181-90. 1999

Detail Information

Publications18

  1. ncbi Broad beneficial effects of cocaine abstinence reinforcement among methadone patients
    K Silverman
    Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    J Consult Clin Psychol 66:811-24. 1998
    ..These results replicate the efficacy of cocaine abstinence reinforcement and show that it can have broad beneficial effects...
  2. ncbi Opioid discrimination in humans: discriminative and subjective effects of progressively lower training dose
    K L Preston
    Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Behav Pharmacol 9:533-43. 1998
    ..These data indicate covariation of subjective effects and discrimination performance and suggest that discrimination behavior may be more sensitive for differentiating among drug conditions than traditional subjective effects measures...
  3. ncbi Shaping cocaine abstinence by successive approximation
    K L Preston
    Intramural Research Program, National Institute on Drug Abuse, Baltimore, Maryland 21224, USA
    J Consult Clin Psychol 69:643-54. 2001
    ..A 2nd phase of the study showed that abstinence induced by escalating-value vouchers can be maintained by a nonescalating schedule, suggesting that contingency management can be practical as a maintenance treatment...
  4. ncbi Cocaine use early in treatment predicts outcome in a behavioral treatment program
    K L Preston
    Intramural Research Program, National Institute on Drug Abuse NIDA, Baltimore, Maryland 21224, USA
    J Consult Clin Psychol 66:691-6. 1998
    ..Cocaine use during baseline provided critical predictors of response to the experimental treatment...
  5. ncbi Evaluation of the abuse potential of methocarbamol
    K L Preston
    Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland
    J Pharmacol Exp Ther 248:1146-57. 1989
    ....
  6. ncbi Monitoring opiate use in substance abuse treatment patients with sweat and urine drug testing
    M A Huestis
    Chemistry and Drug Metabolism Section, National Institute on Drug Abuse Intramural Research Program, Baltimore, Maryland 21224, USA
    J Anal Toxicol 24:509-21. 2000
    ..However, the percentage of false-negative results, at least in this treatment population, indicates that weekly sweat testing may be less sensitive than thrice weekly urine testing in detecting opiate use...
  7. ncbi Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716
    M A Huestis
    National Institute on Drug Abuse Intramural Research Program, 5500 Nathan Shock Dr, Baltimore, MD 21224, USA
    Arch Gen Psychiatry 58:322-8. 2001
    ..These findings suggest that CB1 receptors mediate many of the effects of marijuana, but this has not been evaluated in humans...
  8. ncbi Family history influence on drug abuse severity and treatment outcome
    R W Pickens
    Clinical Neurogenetics Section and Treatment Research Branch, Intramural Research Program, National Institute on Drug Abuse, Baltimore, MD 21224, USA
    Drug Alcohol Depend 61:261-70. 2001
    ..Both effects remained significant after adjusting for gender and race. These results suggest that common genetic factors may underlie both susceptibility to heroin dependence and response to therapeutic methadone treatment...
  9. ncbi Low-dose oral cocaine in humans: acquisition of discrimination and time-course of effects
    D H Epstein
    NIH, NIDA Intramural Research Program, Baltimore, Maryland, USA
    Behav Pharmacol 10:531-42. 1999
    ..Overall, the results support the sensitivity of the behavioral-testing procedure used, and show that 50 mg oral cocaine can serve as a discriminative stimulus in adult humans...
  10. ncbi Naltrexone shortened opioid detoxification with buprenorphine
    A Umbricht
    NIDA Intramural Research Program, Addiction Research Center, Baltimore, MD, USA
    Drug Alcohol Depend 56:181-90. 1999
    ..Peak withdrawal symptoms after naltrexone were of moderate intensity, suggesting that naltrexone combined with buprenorphine is an acceptable and safe treatment for shortened opioid detoxification and induction of naltrexone maintenance...
  11. ncbi Detection of opiate use in a methadone maintenance treatment population with the CEDIA 6-acetylmorphine and CEDIA DAU opiate assays
    A C Spanbauer
    IRP, NIDA, NIH, Baltimore, Maryland 21224, USA
    J Anal Toxicol 25:515-9. 2001
    ..Increasing the opiate screening and confirmation cutoffs for the federal workplace drug-testing program resulted in 8% fewer opiate-positive tests; however, recent heroin use was not affected by this change...
  12. ncbi Opioid drug discrimination in humans: stability, specificity and relation to self-reported drug effect
    W K Bickel
    Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland
    J Pharmacol Exp Ther 251:1053-63. 1989
    ..o.; and secobarbital, 100-200 mg p.o.) did not generalize to hydromorphone, but showed partial generalization to both pentazocine and saline. In general, drug-discrimination performance paralleled the patterns of self reports...
  13. ncbi Effects of agonist-antagonist opioids in humans trained in a hydromorphone/not hydromorphone discrimination
    K L Preston
    Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    J Pharmacol Exp Ther 295:114-24. 2000
    ..These results suggest that instructions are an important factor in the outcome of human drug discrimination studies...
  14. ncbi Cyclazocine: comparison to hydromorphone and interaction with cocaine
    K L Preston
    National Institute on Drug Abuse Intramural Research Program, National Institutes of Health, Department of Health and Human Services, Baltimore, Maryland 21224, USA
    Behav Pharmacol 15:91-102. 2004
    ..This study is suggestive but not strongly supportive for the use of kappa-opiate drugs to diminish acute effects of cocaine administration or for the use of these kappa agonists in drug abuse treatment applications...
  15. ncbi Cigarette smoking and short-term addiction treatment outcome
    P T Harrell
    Intramural Research Program, National Institute on Drug Abuse NIH, Baltimore, MD 21224, USA
    Drug Alcohol Depend 115:161-6. 2011
    ....
  16. ncbi A model for pharmacological research-treatment of cocaine dependence
    I D Montoya
    National Institutes of Health, National Institute on Drug Abuse, Addiction Research Center, Baltimore, MD 21224, USA
    J Subst Abuse Treat 12:415-21. 1995
    ..This model represents an effort to standardize data collection to make results more valid and comparable...
  17. ncbi Subjective and behavioral effects of diphenhydramine, lorazepam and methocarbamol: evaluation of abuse liability
    K L Preston
    Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland
    J Pharmacol Exp Ther 262:707-20. 1992
    ..The considerable overlap in subjective effect measures of positive mood make further differentiation with respect to abuse liability difficult...
  18. ncbi Does cannabis use predict poor outcome for heroin-dependent patients on maintenance treatment? Past findings and more evidence against
    D H Epstein
    Clinical Pharmacology and Therapeutics Branch, Treatment Section, National Institute on Drug Abuse Intramural Research Program, National Institutes of Health, Baltimore, MD 21224, USA
    Addiction 98:269-79. 2003
    ....